Guggenheim Increases Pfizer (NYSE:PFE) Price Target to $35.00

Pfizer (NYSE:PFE) had its price target upped by analysts at Guggenheim from $33.00 to $35.00 in a report issued on Monday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price points to a potential upside of 36.05% from the company’s current price.

PFE has been the topic of a number of other research reports. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Scotiabank started coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.39.

Pfizer Price Performance

Pfizer stock opened at $25.73 on Monday. The stock has a market capitalization of $146.26 billion, a price-to-earnings ratio of 13.68, a PEG ratio of 0.81 and a beta of 0.54. Pfizer has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s 50 day moving average price is $24.91 and its two-hundred day moving average price is $24.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Institutional Trading of Pfizer

Several institutional investors have recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter valued at about $27,000. Curio Wealth LLC increased its position in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer in the second quarter worth $29,000. Finally, Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter valued at $29,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.